Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
  • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/713—Double-stranded nucleic acids or oligonucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications
  • C12N2320/32—Special delivery means, e.g. tissue-specific
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
  • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Definitions

• the present disclosure features methods and compositions for the treatment of neurological diseases; in particular, the methods and compositions feature cells with partial or complete resistance to CSF1R antagonists.
• microglia the resident immune cell of the brain.
• genetic mutations in microglia are the primary cause of neurological disease, whereas, in other diseases, polymorphisms in microglial genes increase the risk of developing the disease.
• therapies for many of these diseases and injuries there are few, if any, effective therapies for many of these diseases and injuries.
• the goal of the present disclosure is to develop microglial-based therapeutics, including approaches to transplant genetically modified human microglia or related monocyte lineages or progenitor cells into patients.
• compositions and methods that allow for differential resistance to CSF1R antagonists (e.g., partial; complete; increase; decrease) for the treatment of neurological diseases..
• Microglia rely on CSF1R signaling via two ligands (CSF1 and IL-34) for survival, proliferation, and self-renewal.
• CSF1 and IL-34 two ligands
• Treatment of mammalian models with various CSF1R antagonists reduces the number of microglia within the central nervous system. Furthermore, when these compounds are removed, surviving microglia proliferate and rapidly refill the niche. Additionally, it has been found that human stem cell-derived microglia transplanted into the murine brain are also susceptible to and killed by CSF1R inhibition (FIG. 11 F, 11G, 11H, 11I, 11 J).
• therapeutic microglia, monocytes, macrophages, or their progenitors or precursors would need to have a selective advantage in comparison to endogenous brain resident microglia in their response to CSF1R inhibitors. Specifically, one would need to develop therapeutic cells that do not die at a given dose of CSF1R inhibitor that is sufficient to kill endogenous microglia. In some instances, this selective advantage should be only partial so that a higher dose of CSF1R inhibitors could also kill therapeutic microglia, macrophages, monocytes, or their progenitors or precursors should the need arise for safety purposes.
• the present disclosure features a cell (e.g., a modified human cell) comprising a nucleic add encoding a modified CSF1R protein (e.g., a human CSF1R protein) exhibiting differential resistance to a CSF1R antagonist.
• a modified human cell exhibiting differential resistance to a CSF1R antagonist.
• the present disclosure features a modified human cell comprising a nucleic add encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• the present disdosure may also feature a method of treating a subject.
• the method may comprise administering a CSF1R antagonist to the subject in a quantity sufficient to inhibit a CSF1R signal in a cell of the subject and contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) having a differential resistance to the CSF1R antagonist.
• a modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the method may comprise contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) having a differential resistance to a CSF1R antagonist and administering the CSF1R antagonist to the subject in a quantity sufficient to inhibit a CSF1R signal in a cell of the subject.
• a modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the present disdosure also features a method of treating a subject.
• the method comprises contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) and differentially altering the proliferation or survival of an unmodified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) relative to the modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte).
• a modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the present disclosure may further feature a nucleic add composition and vectors encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist as described herein.
• transplantation of the aforementioned cells will likely exhibit only partial or limited engraftment into the central nervous system (CNS).
• CNS central nervous system
• the present disclosure develops the currently described approach that will significantly facilitate the therapeutic engraftment of microglia, macrophages, or monocytes or their progenitors (HSPCs, PMPs) in the mammalian brain. None of the presently known prior references or work has the unique, inventive technical feature of the present invention.
• compositions and methods of this disclosure represent a significant departure from the current paradigm for the use of CSF1R antagonists in medicine.
• the prior art teaches the use of a CSF1R inhibitor to clear endogenous microglia and facilitate the entry of bone marrow- and/or blood-derived monocytes into the brain.
• bone marrow- and/or blood-derived monocytes that infiltrate the brain remain functionally and transcriptionally distinct from microglia even many months after infiltration.
• the bone marrow- and/or blood-derived monocytes do not have the same sensitivity to CSF1R antagonists as microglia, demonstrating that these cells are not microglia.
• therapeutic microglia e.g., human microglia
• a modified CSF1R protein for the treatment of neurological diseases.
• CSF1R antagonists compounds for the treatment of some forms of cancer.
• endogenous microglia are extremely sensitive to CSF1R antagonists and will die in response to treatments with higher doses of these compounds. This is true of human stem cell-derived microglia transplanted into the murine brain (FIG. 11F, 11G, 11H, 11I, 11J). and cultured human microglia as well (FIG. 4A, 4B, 4C, 4D, and 4E).
• the present disdosure utilizes compounds (e.g., CSF1R antagonist) that are toxic to microglia in order to improve the long-term engraftment of transplanted microglia (e.g., transplanted therapeutic microglia; i.e., microglia comprising a modified CSF1R protein).
• transplanted microglia e.g., transplanted therapeutic microglia; i.e., microglia comprising a modified CSF1R protein.
• the present disclosure features methods and compositions to facilitate the competitive engraftment of human microglia, macrophages, and monocytes and/or their precursor cells (HSPCs, erythromyeloid progenitors (EMPs), or Primitive Macrophage Progenitors (PMPs)).
• HSPCs human microglia, macrophages, and monocytes and/or their precursor cells
• EMPs erythromyeloid progenitors
• PMPs Primitive Macrophage Progenitors
• Cells can be derived from a variety of sources, including but not limited to pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells (iPSCs), bone marrow-derived hematopoietic stem cells, cord blood cells, blood-derived monocytes, fetal yolk sac or tissue macrophages, adult tissue-derived macrophages, or through direct reprogramming of another cell type into a microglia, HSPC, monocyte, or macrophage. Additionally, the present disclosure may feature methods and compositions to facilitate the competitive engraftment of CSF1R expressing cells, including but not limited to cells from the heart, skin, liver, lungs, kidney, eye, prostate, and ovary.
• pluripotent stem cells including embryonic stem cells and induced pluripotent stem cells (iPSCs), bone marrow-derived hematopoietic stem cells, cord blood cells, blood-derived monocytes, fetal yolk sac or tissue macrophages, adult tissue-derived macrophage
• FIG. 1 shows in vitro growth kinetics of control and CSF1R mutant microglia.
• Isogenic iPSC-derived hematopoietic progenitors were differentiated towards microglia, and cell density was used for the first 14 days.
• the two wild-type isogenic control lines (Cntl-1 and Cntl-2) demonstrate that some degree of variability is expected in the proliferation rates of iPSC-microglia.
• Both the hCSF1 R G795A and G785C mutants exhibit proliferation rates that are comparable to the two control lines.
• the hCSFR G794V mutant exhibits a rapid reduction in cell density, with no viable cells remaining beyond day 6 of differentiation.
• FIG. 2A, 2B, 20, 2D, 2E, and 2F show selected CSF1R mutations have little effect on transcriptomic signature while simultaneously imparting resistance to PLX5622.
• FIG. 2A shows a principal component analysis using the top 2,000 genes reveals that the primary source of variation in the dataset is the WT response to PLX5622.
• FIG. 2B and FIG. 20 shows a linear regression analysis and calculation of the Pearson correlation coefficient between DMSO-treated MUT1 (i.e., G795A; FIG. 2B) or MUT2 (i.e., G795C; FIG. 20) and WT microglia confirmed a high degree of concordance when examining the full transcriptome, and the 249 genes core microglial gene signature.
• FIG. 1 shows a principal component analysis using the top 2,000 genes reveals that the primary source of variation in the dataset is the WT response to PLX5622.
• FIG. 2B and FIG. 20 shows a linear regression analysis and calculation of the Pearson correlation coefficient between
• 2D, 2E, and 2F show a 24-hour treatment of WT (FIG. 2D), MUT1 (i.e., G795A, FIG. 2E), and MUT2 (i.e., G795C; FIG. 2F) microglia with PLX5622 induced significant transcriptomic alterations in the WT cells (FDR ⁇ 0.05; log2(FC) ⁇ ⁇ 1) when compared to DMSO-treated cells.
• FDR ⁇ 0.05; log2(FC) ⁇ ⁇ 1 induced significant transcriptomic alterations in the WT cells
• treatment of both the MUT1 and MUT2 lines failed to significantly alter gene expression, suggesting that these lines are resistant to the effects of PLX5622.
• FIG. 3 shows a distance matrix of CSF1R mutants and control xMGs (microglia). RNA-seq expression counts were normalized and transformed using a variance stabilizing transformation. Pairwise Euclidean distances were calculated between all samples, and samples were hierarchically clustered by distance. These data demonstrate that the transcriptome of G795A mutant microglia is most equivalent to that of WT CSF1 R microglia.
• FIG. 4A, 4B, 4C, 4D, and 4E show human stem cell-derived microglia are also susceptible to and killed by CSF1R inhibition in vitro.
• FIG. 4A shows caspase 3/7 levels imaged over 24 hours in culture with complete medium with 0.1%DMSO, 250nm PLX3397, 500nm PLX3397, and 1 ⁇ m PLX 3397. Images captured on Incucyte S3 live-cell imager.
• FIG. 4B shows caspase 3/7 levels imaged over 24 hours in culture with complete medium with 0.1%DMSO, 250nm PLX5622, 500nm PLX5622, and 1 ⁇ m PLX5622. Images captured on Incucyte S3 live-cell imager.
• FIG. 4A shows caspase 3/7 levels imaged over 24 hours in culture with complete medium with 0.1%DMSO, 250nm PLX5622, 500nm PLX5622, and 1 ⁇ m PLX5622. Images captured on Incucy
• FIG. 4C shows caspase 3/7 levels imaged over 24 hours in culture with complete medium with 0.1%DMSO, 250nm Edicotinib (JNJ-40346527), 500nm Edicotinib, and 1 ⁇ m Edicotinib. Images captured on Incucyte S3 live-cell imager.
• FIG. 4D shows caspase 3/7 levels imaged over 24 hours in culture with complete medium with 0.1%DMSO, 250nm BLZ945, 500nm BLZ945, and 1 ⁇ m BLZ945. Images captured on Incucyte S3 live-cell imager.
• 4E shows representative images of caspase 3/7 fluorescent activity for Wildtype, G795A, and G795C microglia after 24 hrs in culture with PLX3397.
• n 4 images in six independent wells were quantified. Data represented as mean values ⁇ SEM.
• FIG. 5A and 5B show G795A iPSC-derived microglia are resistant to CSF1R antagonist-induced cell death.
• G795A and wild-type (WT) iPSC-microgiia were treated for 24 hours with either 500nM (FIG. 5A) or 1uM (FIG. 5B) of DMSO vehicle control or one of four CSF1R antagonists; PLX3397, PLX5622, Edicotinib, and BLZ945.
• the percent of live versus dead cells was then quantified using a two-color viability/cytotoxicity approach (Thermo L3224; LIVE/DEADTM Viability/Cytotoxicity Kit). Very few dead microglia are observed 24 hours after treatment with DMSO. In contrast, treatment with CSF1R antagonists induces substantial cell death in wild-type microglia but little-to-no cell death in G795A microglia. Live cells are denoted with a circle.
• Microglia expressing CSF1R G795A phosphorylate similarly, while microglia expressing CSF1R G795C demonstrate elevated levels of phosphorylation in comparison to WT microglia.
• FIG. 7A, 7B, 7C and 7D show the crystal structure of the CSF1R receptor bound to a CSF1R antagonist.
• FIG. 7A shows a human CSF1R receptor bound to a PLX5622 CSF1R antagonist
• FIG. 7B shows a CSF1R receptor bound to a PLX3397CSF1R antagonist.
• the crystal structure was examined to predict amino acid substitutions that may sterically hinder the binding of CSF1R antagonists while not impairing the normal binding of ATP into the same binding pocket.
• the crystal structure of the CSF1R antagonist PLX5622 (FIG. 7A) or PLX3397 (FIG. 7B) bound to human CSF1R was previously published.
• FIG. 8 shows DNA chromatograms demonstrate the successful production of isogenic human iPSC cell lines that encode single amino acid point mutations at position 795 within the CSF1R coding sequence.
• each line was generated via CRISPR-mediated gene editing.
• similar changes could be introduced via various other gene-editing methods, including but not limited to TALENs, traditional homologous recombination, viral gene delivery, or other CRISPR variants.
• FIG. 9A, 9B, 9C, 9D, and 9E show selected CSF1R mutations have little effect on transcriptomic signature in vivo.
• FIG. 9A shows a principal component analysis using the top 2,000 genes reveals that the primary source of variation between G795A, G795C, and WT microglia is attributed to individual animals and not CSF1R mutations. In contrast, when G795V is compared there is some separation based on this mutation, further indicating that G795V may not enable the generation of microglia without substantially altering gene expression.
• FIG. 9B and 9C show a linear regression analysis and calculation of the Pearson correlation coefficient between G795A (FIG. 9B) or G795C (FIG.
• FIG. 9C shows a high degree of concordance when examining the full transcriptome and the 190 genes core microglial signature.
• FIG. 9D and 9E show a volcano plot of human microglia explanted 2-months post-transplantation in MITRG mice exhibit minimal significant transcriptomic alterations in the mutant cells (FDR ⁇ 0.05; log2(FC) ⁇ ⁇ 1) when compared to WT cells.
• FIG. 10A and 10B show G795A iPSC-derived microglia exhibit transcriptome signatures following xenotransplantation in vivo that are highly similar to that of isogenic wild-type iPSC-derived microglia.
• Xenotransplantation-compatible mice were engrafted with either wild-type (WT) or G795A iPSC-microglia, and after two months, human cells were isolated and examined via bulk RNA sequencing.
• FIG. 10A shows a correlation across all detected genes is shown for xMGs isolated from individual WT and G795A engrafted mice. Differences between individual mouse recipients lead to some variability, but WT and G795 xMGs remain highly correlated with R 2 between 0.80 and 0.95.
• FIG. 10A shows a correlation across all detected genes is shown for xMGs isolated from individual WT and G795A engrafted mice. Differences between individual mouse recipients lead to some variability, but WT and G795 xMGs remain highly correlated with
• FIG. 11A, 11B, 11C, 11D, 11E, 11F, 11G, 11H, 11I, and 11 J show G795A iPSC-derived microglia are resistant to CSF1R agonist treatment and enable robust engraftment of human microglia within the adult mammalian brain.
• Xenotransplantation-compatible mice received bilateral stereotactic intrahippocampal injections of 500,000 iPSC-derived human microglia (xMGs) at 2-months of age. Mice received xMGs differentiated from either a homozygous CSF1R-resistant G795A human iPSC line or an isogenic unmodified Wild-Type human iPSC.
• FIG. 11A-11E shows that over the course of one-month PLX3397 treatment, G795A xMGs proliferate and expand from the initial injection sites within the hippocampus and cortex.
• Microglia are labeled with IBA-1 (FIG. 11 A and 11 F), human-specific marker Ku80 (FIG. 11B and 11G) is used to co-iabel foe nuclei of human microglia, and Ki67 (FIG.
• FIG. 11C and 11 H is used to demonstrate ‘wavefronts' of proliferative human xMGs migrating toward remaining unoccupied niches within foe cortex and thalamus (arrows).
• FIG. 11E shows a higher power image of foe boxed region in FIG. 11D demonstrates that all IBA1+ microglia co-express Ku80.
• FIG. 11 F - 11I shows a handfol of wild-type human xMGs survive one month of PLX3397 treatment.
• foe arrows in FIG. 11 J reveals just four surviving xMGs within foe boxed region shown in FIG. 11I.
• FIG. 12 shows quantification of CSF1R-G795A human iPSC-microglial engraftment following transplantation into adult hCSF1 mice.
• Transplantation of CSF1R-G795A iPSC-microglia into a fully occupied adult microglial niche without treatment with CSF1R antagonists, produces very limited engraftment of human microglia (5-10% of total microglia) as measured by co-localization of the microglial marker IBA1 and the human-spedfic nuclear marker Ku80 (Ku80+/lba1+).
• a “CSF1R expressing cell” may refer to cells that express CSF1R or cells that may be induced to express CSF1R or cells that are differentiated into cells that express CSF1R.
• Non-limiting examples of CSF1R-expressing cells may include but are not limited to microglia, monocytes, HSPCs (hematopoietic stem or progenitor cells), macrophages, dendritic cells, Langerhans cells, Kupffer cells, Hofbauer cells, Extravillous trophoblasts, phagocytes, or primitive macrophages from pluripotent stem cells.
• a CSF1R expressing cell may refer to microglia that has been directly reprogrammed from iPSCs, monocytes, or fibroblasts via either genetic or small molecule approaches.
• CSF1R expressing phagocyte may refer to a cell that expresses the CSF1R receptor and has the capacity for phagocytosis; the process by which a cell uses its plasma membrane to engulf extracellular particles or bacteria, substrates, proteins, lipids, or aggregates and then internalizes this region to form a phagosome.
• Non-limiting examples of CSF1R-expressing phagocytes may include but are not limited to microglia, macrophages, monocytes, dendritic cells, or other phagocytes.
• a CSF1R-expressing phagocyte is a CSF1R-expressing cell.
• differential resistance may refer to a state occurring in a modified cell in which the inhibition by a CSF1 R antagonist of a CSF1 R signal exhibits a different dose-response relationship or magnitude of response than is observed in an unmodified cell.
• differential resistance may refer to altering the proliferation or survival of an unmodified CSF1R-expressing cell relative to the modified CSF1R-expressing cell.
• differential resistance may comprise a partial, complete, increased, or decreased resistance to a CSF1R antagonist.
• CSF1R signal inhibition may refer to a dose-dependent reduction caused by a CSF1 R antagonist in a step of a CSF1 R signaling cascade, such as phosphorylation or dephosphorylation events, gene expression, etc.
• partial resistance refers to modified cells that are still destroyed by higher doses of CSF1 R antagonist. Partial resistance could be due to increased binding constant (Kd) or ATP, reduced kinase activity, reduced binding affinity to CSF1 ligand, or reduced signal transduction.
• complete resistance refers to modified cells in which CSF1R signal inhibition never occurs at any concentration of the antagonist.
• an “increased resistance” refers to modified cells in which CSF1 R signal inhibition occurs at an increased concentration of the antagonist relative to what is observed in unmodified cells.
• a ‘decreased resistance" refers to modified cells in which CSF1R signal inhibition occurs at a lower concentration of a receptor antagonist relative to what is observed in unmodified cells.
• a subject can be a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, mice, etc.) or a primate (e.g., monkey, ape, and human).
• the subject is a human.
• the subject is a mammal (e.g., a human) having a disease, disorder, or condition described herein.
• the subject is a mammal (e.g., a human) at risk of developing a disease, disorder or condition described herein.
• the term patient refers to a human under medical care or animals under veterinary care.
• neurological diseases refers to injuries, trauma, disorders, or diseases that affect the brain as well as the nerves found throughout the body and the spinal cord.
• the terms “treat” or “treatment” or “treating” refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow the development of the disease (e.g., a neurological disease), such as slowing down the development of a disorder, or reducing at least one adverse effect or symptom of a condition, disease or disorder, e.g., any disorder characterized by insufficient or undesired organ or tissue function.
• Treatment is generally "effective'' if one or more symptoms or clinical markers are reduced, as that term is defined herein.
• a treatment is "effective” if the progression of a disease is reduced or halted.
• treatment includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment.
• Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of the extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
• Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
• Treatment also includes ameliorating a disease, lessening the severity of its complications, preventing it from manifesting, preventing it from recurring, merely preventing it from worsening, mitigating an inflammatory response included therein, or a therapeutic effort to affect any of the aforementioned, even if such therapeutic effort is ultimately unsuccessful.
• the present disclosure features methods and compositions for the creation and use of therapeutically designed CSF1R-expressing cells (e.g., therapeutic microglia) that have a differential resistance to CSF1 R antagonists for the treatment of neurodegenerative diseases.
• therapeutically designed CSF1R-expressing cells e.g., therapeutic microglia
• CSF1R antagonists for the treatment of neurodegenerative diseases.
• Cells within the central nervous system can exist inside a ‘niche’ which can limit the total number of cells that can reside within the mammalian CNS.
• the present disclosure aims to use CSF1R-expressing cells (e.g., CSF1R expressing phagocytes, HSPCs, dendritic cells, erythromyeloid progenitors, microglia, macrophages, or monocytes) to develop new treatments for neurological disease and injury.
• CSF1R-expressing cells e.g., CSF1R expressing phagocytes, HSPCs, dendritic cells, erythromyeloid progenitors, microglia, macrophages, or monocytes
• CSF1R-expressing cells e.g., CSF1R expressing phagocytes, HSPCs, dendritic cells, erythromyeloid progenitors, microglia, macrophages, or monocytes
• the present disclosure features modified CSF1R-expressing cells or their progenitors or stem cells that are differentiated into cells that express CSF1R, wherein the modified CSF1R-expressing cells have differential resistance to CSF1R antagonists.
• methods of making modified cells according to the present disclosure may include, in the case of an induced pluripotent stem cells (iPSC)- or hematopoietic stem and progenitor cells (HSPCs)- derived modified cell, introducing a modification into an undifferentiated cell, optionally screening or selecting for the modification, and differentiating the modified cell into a cell or cell lineages such as a monocyte or macrophage lineage.
• iPSC induced pluripotent stem cells
• HSPCs hematopoietic stem and progenitor cells
• the present disclosure features a cell (e.g., a human cell) exhibiting differential resistance to a CSF1R antagonist.
• the present disclosure features a modified human cell exhibiting differential resistance to a CSF1R antagonist.
• the present disclosure may also feature a cell (e.g., a human cell) comprising a nucleic acid encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• the present disclosure features a modified human cell comprising a nucleic acid encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• the cell (e.g., a human cell) of the present disclosure expresses CSF1R and may be a CSF1R-expressing cell. In other embodiments, the cell (e.g., a human cell) of the present disclosure can be induced or differentiated to express CSF1R.
• the present disclosure may also feature a modified cell as described herein that is expressing CSF1R.
• the present disclosure features a modified human cell as described herein that is expressing CSF1R.
• the cell may be induced and/or differentiated to express CSF1R and may be selected from a group consisting of pluripotent stem cell, hematopoietic stem cell, an erythromyeloid progenitor, and hematopoietic progenitor cell.
• CSF1R-expressing cells may include but are not limited to microglia, macrophages, monocytes, or other phagocytes.
• cells that can be induced or differentiated to express CSF1R may include but are not limited to pluripotent stem cell, hematopoietic stem cell, an erythromyeloid progenitor, or a hematopoietic progenitor cell.
• the modified cell e.g., the modified human cell
• the modified cell is a precursor cell including but not limited to microglia, monocytes, macrophages, hematopoietic progenitor cells (MFCs) and hematopoietic stem cells (HSCs), erythromyeloid progenitors (EMPs), primitive macrophages, and primitive macrophage progenitors (PMPs) or cord blood hematopoietic stem cells.
• MFCs hematopoietic progenitor cells
• HSCs hematopoietic stem cells
• EMPs erythromyeloid progenitors
• primitive macrophages primitive macrophages
• PMPs primitive macrophage progenitors
• the modified cells are differentially resistant to CSF1R antagonists.
• CSF1R antagonists may include but are not limited to PLX5622, PLX3397 (pexidartinib), BLZ945, Ki20227, JNJ-40346527; JNJ-527 (Edicotinib), cFMS Receptor Inhibitor II, AZ304, ARRY-382, YM-90709, GW2580, PLX108-01, PLX7486, PLX647, ARRY-382, JNJ-40346527, Emactuzumab (RG7155), AMG820, IMC-CS4 (LY3022855), MCS110, BPR1R024, AZD7507, JTE-952, JNJ-28312141, c-FMS-IN-8, rr CSF1R-IN-22.
• a CSF1R antagonist may include any compound that inhibits CSF1R interaction with its cognate ligands (e.g., CSF1 or IL-34), substrates, or downstream effectors.
• CSF1R interaction with its cognate ligands e.g., CSF1 or IL-34
• Non-limiting examples of compounds that inhibit CSF1 R interaction with its cognate ligands, substrates, or downstream effectors include but are not limited to antibodies or drugs that block the interactions between CSF1R and Phospholipase C-gamma2 (PLCg2), Spleen tyrosine kinase (Syk), and the Grb2/Gab2/Shp2 complex.
• PHCg2 Phospholipase C-gamma2
• Grb2/Gab2/Shp2 complex e.g2
• differential CSF1R antagonist resistance is conferred by modifying genes downstream of CSF1
• Non-limiting examples may include but are not limited to INPP5D (SHIP1), TREM2, DAP12, PLCG2, PI3K, AKT, PKG, FIMP, JNK, A-SMase, spleen tyrosine kinase (Syk), and the Grb2/Gab2/Shp2 complex.
• partial CSF1R antagonist resistance is conferred by pretreating microglia with agonists or antagonists of CSF1R signaling.
• CSF1R antagonists may include any compound that inhibits CSF1R signaling by blocking the ATP binding site (i.e., the ATP binding pocket).
• Table 1 shows a wild type CSF1R sequence and non-limiting examples of modified CSF1R amino acid sequences (i.e., modified CSF1R protein described herein) as well as non-limiting examples of the nucleic adds sequences encoding the modified CSF1R protein described herein.
• modified CSF1R amino acid sequences i.e., modified CSF1R protein described herein
• nucleic adds sequences encoding the modified CSF1R protein described herein.
• Examples of such nudeic adds indude those with one or more silent or conserved nucleic add substitutions compared to the wild type nudeic acid sequence.
• Bolded nudeic acids (NAs) are examples of where one or more silent or conserved nucleic add substitutions may be incorporated into the sequence. Potential nudeic acids are highlighted in the description.
• the cell comprises one or more genetic modifications in a gene for a CSF1R receptor (i.e., CSF1R protein).
• the cell comprises one or more genetic modifications in a CSF1R protein (i.e., a CSF1R receptor).
• the one or more genetic modifications in the CSF1R receptor do not induce constitutively active CSF1R signaling.
• the modified CSF1R receptor i.e., CSF1R protein
• the ligand of the CSF1R protein may include but is not limited to CSF1, IL-34, a CSF1R agonist or activating antibody, or a combination thereof.
• the modified CSF1R protein is activated by a CSF1 ligand.
• the CSF1 ligand induces phosphorylation of the modified CSF1R protein.
• the modified CSF1R protein is activated by an IL-34 ligand.
• the IL-34 ligand induces phosphorylation of the modified CSF1R protein.
• the one or more genetic modifications result in a modified ATP binding pocket.
• the modified ATP binding pocket of the CSF1R receptor i.e., CSF1R protein
• the modified ATP binding pocket cannot bind a drug (e.g., a CSF1R antagonist or agonist).
• the modified ATP binding pocket can bind ATP.
• the one or more genetic modifications in the CSF1R receptor do not interfere with the ATP binding activity of the CSF1R protein.
• the one or more genetic modifications in the CSF1 R receptor lack a pocket for a drug (e.g., a CSF1R antagonist or agonist) to bind but do not interfere with the normal ATP binding activity of the CSF1R protein.
• a drug e.g., a CSF1R antagonist or agonist
• the one or more genetic modifications is a point mutation. In some embodiments, the one or more genetic modifications result in a single amino acid substitution. In other embodiments, the one or more genetic modifications result in single amino acid insertion. In further embodiments, the one or more genetic modifications result in single amino acid deletion.
• the one or more genetic modifications result in a change in the amino add sequence of the CSF1R protein.
• the change in the amino add sequence may optionally comprise the substitution of an amino add residue selected from G795, L785, M637, E633, and V647.
• the one or more genetic modifications result in an amino add substitution.
• the one or more genetic modifications result in a single amino acid substitution.
• the single amino add point mutations may be selected from a group consisting of G795A, G795V, and G795C.
• the CSF1 R gene is modified to confer partial or complete resistance to the CSF1R antagonist in the modified cells.
• the CSF1R gene is modified with a single point mutation.
• single point mutations of the CSF1R gene may include but are not limited to these single amino add substitutions at positions G795, L785, M637, E633, and/or V647.
• substitutions may comprise G795A, G795V, or G795C, or G795D, or G795E, or G795F, or G795G, or G795H, or G795I, or G795K, or G795L, or G795M, or G795N, or G795P, or G795Q, or G795R or G795S, or G795T, or G795W, or G795Y.
• substitutions with amino acids with less bulky side chains such as glycine or alanine may improve binding to antagonist spedes that are only weakly bound by the native sequence due to steric hindrance by slightly larger or incompatibly polar side chains.
• amino acids with less bulky side chains such as glycine or alanine may improve binding to antagonist spedes that are only weakly bound by the native sequence due to steric hindrance by slightly larger or incompatibly polar side chains.
• the one or more genetic modifications result in a change in a plurality of amino adds of the CSF1R protein.
• the change in a plurality of amino acids are to adjacent amino adds. In other embodiments, the change in a plurality of amino acids are to non-adjacent amino adds.
• the one or more genetic modifications are within the ATP-binding pocket of the CSF1R protein (i.e., a CSF1R receptor). In other embodiments, the one or more genetic modifications (e.g., point mutations) are outside the ATP-binding pocket of the CSF1R protein (i.e., a CSF1R receptor). Without wishing to limit the present disclosure to any theories or mechanisms, it is believed that mutations outside the ATP-binding pocket of the CSF1 R protein may work through allostery to inhibit antagonist binding.
• the one or more genetic modifications are introduced ex vivo.
• the one or more genetic modifications are induced by transfecting or introdudng into a cell (e.g., a human cell) a nucleic add encoding a transgene.
• the one or more genetic modifications are introduced by transduction or introduction of a targeted nudease, nickase, or base-editing effector or ribonudeoprotein complex.
• introducing the nudeic add encoding a transgene in a cell comprises contacting the cell (e.g., the human cell) with a viral vector.
• the one or more genetic modifications (e.g., point mutations) in the CSF1R gene are generated via site-directed or random mutagenesis methods known in the art, including, without limitation, CRISPR-Cas, TALEN, and ZFN genome editing systems.
• modified CSF1R transgenes may be introduced into cells (e.g., human cells) by, e.g., DNA or RNA vectors such as naked nucleic acids, liposome or other encapsulated nucleic add vectors, artificial chromosomes, and/or viral vectors such as lentiviral and adeno-assodated viral vectors.
• cells comprising a modified CSF1R protein as described herein retain a gene expression profile of a cell (e.g., a human cell) comprising a wild-type CSF1R protein.
• in vitro cells e.g., in vitro human cells
• in vitro human cells have a similar gene expression profile as in vitro cells (e.g., in vitro human cells) comprising a wild-type CSF1R protein.
• cells comprising a modified CSF1R protein that are transplanted in vivo have a similar gene expression profile of a transplanted cell (e.g., human cell) that does not compromise a modified CSF1R protein.
• modified CSF1R-expressing cells e.g., CSF1R-expressing phagocytes
• retain a gene expression profile of wild-type CSF1R-expressing cells e.g., CSF1R-expressing phagocytes.
• the present disclosure may also feature a composition comprising a CSF1R-expressing cell as described herein.
• the present disdosure may also feature a composition comprising a CSF1R-expressing phagocyte as described herein.
• the composition comprises a plurality of cells. In some embodiments, at least 0.1%, at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40, at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 99% or at least 99.5% of the plurality of cells are CSF1R-expressing cells having differential resistance to a CSF1R antagonist.
• At least 0.1%, at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40, at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 99% or at least 99.5% of the plurality of cells are CSF1R-expressing phagocytes having differential resistance to a CSF1 R antagonist.
• the present disdosure features a method of treating a subject.
• the method comprises administering a CSF1R antagonist to the subject in a quantity suffident to inhibit a CSF1R signal in a cell of the subject and contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) having a differential resistance to a CSF1R antagonist.
• a modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the method comprises contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) having a differential resistance to a CSF1R antagonist and administering the CSF1R antagonist to the subject in a quantity sufficient to inhibit a CSF1R signal in a cell of the subject.
• a modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• differential resistance to the CSF1R antagonist is partial resistance or complete resistance to the CSF1 R antagonist.
• the modified CSF1R-expressing cells may further comprise one or more modifications (e.g., one or more genetic modifications in another gene (e.g., outside of the CSF1R gene).
• the modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the gene product is not otherwise expressed by the CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte).
• the modified CSF1R-expressing cell expresses other genetic modifications useful to treat, cure, ameliorate, prevent or palliate a neurological disease.
• other genetic modifications outside of the CSF1R gene are used to correct a mutated gene to treat a disease caused by mutations in that other gene.
• the CSF1R signal that is inhibited by the CSF1R antagonist is the proliferation or survival of a CSF1R-expressing cell (e.g., a CSF1R-expressing phagocyte) that is endogenous to the subject.
• the CSF1 R antagonist is administered to the subject in a quantity sufficient to reduce the proliferation or survival of the endogenous CSF1R-expressing cell (e.g., a CSF1R-expressing phagocyte) of the subject relative to the modified CSF1R-expressing cell (e.g., a modified CSF1R-express phagocyte).
• the present disclosure may also feature a method of treating a subject.
• the method may comprise contacting the subject with a modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte) and differentially altering the proliferation or survival of an unmodified CSF1R-expressing cell (e.g., an unmodified CSF1R-expressing phagocyte) relative to the modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte).
• the modified CSF1R-expressing cell e.g., a modified CSF1R-expressing phagocyte
• the step of differentially altering the proliferation or survival of the unmodified CSF1R-expressing cell comprises administering the CSF1R antagonist to the subject in a quantity sufficient to reduce proliferation or survival of the unmodified CSF1R-expressing cell (e.g., an unmodified CSF1R-expressing phagocyte) relative to the modified CSF1R-expressing cell (e.g., a modified CSF1R-expressing phagocyte).
• the methods described herein may kill about 0.1%, or about 1%, or about 5%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 99%, or about 99.5% of endogenous CSF1R-expressing phagocyte within the CNS of the subject. In other embodiments, the methods described herein may kill all the endogenous CSF1R-expressing phagocytes within the CNS of the subject.
• the methods described herein may further allow for the engraftment of about 0.1%, or about 1%, or about 5%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 99%, or about 99.5% of the modified CSF1R-expressing phagocyte within the CNS of the subject.
• the methods described herein allow for complete engraftment of the modified CSFIR-expressing phagocyte within the CNS of the subject.
• a neurological disease comprises a disease of the nervous system.
• neurological diseases may include but are not limited to dementia, a neurodegenerative disease, a genetic disease, a spinal cord injury, a traumatic brain injury, a disease caused or worsened by exposure to a chemical or other agent, etc.
• the present disclosure may also feature a composition for the treatment of neurological disease, the composition comprising a plurality of modified cells having differential (e.g., increased, decreased, partial or complete) resistance to CSF1R antagonists.
• the modified cells are CSFIR-expressing cells.
• the present disclosure may further feature nucleic add compositions and vectors encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist as described herein.
• the nudek: acid compositions and vectors may indude a payload including but not limited to a transgene, a marker or reporter gene, etc.
• the expression vector comprises a nucleic acid composition as described herein operably linked to an expression control sequence.
• the nucleic acid composition comprises a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• the differential resistance to the CSF1R antagonist is partial resistance, complete, increased, or decreased resistance to the CSF1R antagonist.
• the nucleic acid composition comprises a modified CSF1R protein comprising one or more genetic modifications.
• the one or more genetic modifications result in an amino acid substitution which is selected from a group consisting of G795A, G795V, G795C, L785, M637, E633, and V647.
• the present disclosure features an expression vector comprising a nucleic acid composition comprising a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• the expression vectors described herein may be used to modify cultured or endogenous cells.
• the expression vectors described herein are used to transfect a cultured cell, such that the culture cell or the progeny of said cell express the polypeptide.
• the expression vectors described herein are used to modify an endogenous CSF1R-expressing cell by transducing the nucleic acid (e.g., by infecting with the viral vector to create a CSF1R-antagonist resistant cell in situ).
• Methods and compositions of the present disclosure may advantageously be used in human or veterinary applications whereby a modified cell or a vector or genome-editing-system (e.g, a CRISPR-Cas, TALEN, or ZFN system) configured to introduce a mutation of the instant disclosure and thereby create a modified cell, is used in the prevention, palliation, amelioration or cure of a disease or disorder.
• a modified cell or a vector or genome-editing-system e.g, a CRISPR-Cas, TALEN, or ZFN system
• these methods will comprise the steps of contacting a subject with a modified cell or a vector or genome editing system configured to generate such a cell and contacting the subject with a CSF1R antagonist.
• any subject may be a candidate for treatment according to these methods, but it may be advantageous to treat those subjects who suffer from, or are predicted or predisposed to suffering from, a disease such as a neurological disease that can be prevented, palliated, ameliorated or cured by contacting the subject with a cell of the present disclosure characterized by a differential response to CSF1R antagonists relative to a native or endogenous cell of the subject.
• a disease such as a neurological disease that can be prevented, palliated, ameliorated or cured by contacting the subject with a cell of the present disclosure characterized by a differential response to CSF1R antagonists relative to a native or endogenous cell of the subject.
• a neurological disease amenable to treatment by methods of this disclosure may comprise dementia, a neurodegenerative disease, a demyelinating disease, a mood or personality disorder, a traumatic brain injury, a genetic disease, a malignant or benign tumor, a metastatic tumor, or growth, etc.
• a subject can be contacted with a modified cell or a vector of the disclosure at any suitable time and by any suitable route of administration, including without limitation by intravenous, intramuscular, intraperitoneal, intraparenchymal, intrathecal, intercranial, interosseus or other injection or infusion, transdermal administration (for vectors) and/or by surgical implantation or transplantation.
• Any suitable number of cells or titer of the vector may be administered, e.g., 10 1 , 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , etc. cells, and/or 10 14 , 10 13 , 10 12 , 10 11 , 10 10 , 10 9 , or fewer virions or viral genomes.
• the cells with which the subject is contacted may be derived from the subject's own cells (autologous cells) or they may be from another donor (allogeneic cells).
• CSF1R antagonists may be most clearly manifest in the presence of a CSF1R antagonist. Therefore, while the subject may be contacted at any time with a CSF1R antagonist (including without limitation as pre-treatment or conditioning treatment prior to contacting a subject with a modified cell of this disclosure), some embodiments of this disclosure comprise administering a CSF1R antagonist to a subject simultaneously with and/or following the step of contacting the subject with the modified cell or vector.
• the CSF1R antagonist may be administered continuously or discontinuously, and the initiation or discontinuation of the administration may be scheduled or pre-programmed, or it may be in response to a physiological readout from the subject such as a biomarker concentration, a serum or tissue concentration of a biomarker or a small molecule active ingredient or metabolite thereof, an imaging signal or sign, etc.
• said CSF1R antagonist may be administered to a subject to reduce the proliferation or survival of native cells within a niche occupied by such cells, thereby imparting a selective advantage to modified cells and optionally increasing a rate of engraftment or other behavior of the modified cells relative to that observed in the absence of the CSF1R antagonist.
• This administration may be initiated - and optionally terminated - prior to, simultaneously, or subsequently to the step of contacting the subject with the modified cell or vector.
• a CSF1R antagonist may be administered to a subject prior to, coincident with, and/or subsequent to the transplantation of modified microglial-lineage cells to limit the proliferation and/or survival of endogenous microglia, thereby imparting an advantage to the modified microglia which may result in a greater degree of engraftment and/or a greater spatial distribution of the modified microglia than might otherwise be observed.
• a modified cell of this disclosure may exhibit increased sensitivity to CSF1R antagonists relative to an unmodified cell.
• the CSF1R antagonist is generally (but not necessarily) withheld before and during the step of contacting the subject with the modified cell, and instead is administered after the subject has been contacted with the modified cell or vector, for instance, to limit the proliferation or survival of the modified cells at the conclusion of a course of treatment, in response to a signal from a physiological or pharmacological measurement, and/or in response to an adverse event or a reduction in the efficacy of a therapeutic intervention utilizing the modified cells.
• a modified cell of this disclosure optionally comprises one or more additional modifications relative to a native cell, of the same type. These modifications may include, without limitation, one or more transgenes, or one or more genetic modifications that correct a mutation or reduce or increase the expression of a gene product.
• this disclosure includes a microglial cell engineered to express a CSF1R allele with reduced sensitivity to a CSF1R antagonist, and a secreted transgene such as an enzyme or a binding protein, an RNA such as antisense, miRNA, or siRNA, a cell surface protein such as a chimeric antigen receptor, a membrane-bound immunoglobulin or fragment thereof, an aptamer, etc.
• the disclosure also comprises vectors and methods of making such cells substantially as described above, and a method of treating a subject using a cell or vector to treat the subject.
• HPCs hematopoietic progenitor cells
• HSCs hematopoietic stem cells
• EMPs erythromyeloid progenitors
• PMPs Primitive Macrophage Progenitors
• Strategy 1 A crystal structure of the CSF1R receptor bound to an antagonist (PMID: 31434879) to predict amino acid substitutions that may sterically hinder the binding of CSF1R antagonists while not impairing the normal binding of ATP into the same binding pocket.
• the crystal structure of PLX5622 bound to human CSF1R was obtained and the ATP binding pocket was examined (FIG. 7A). Through molecular modeling single amino add changes were predicted that would likely impair the binding of PLX5622 or PLX3397 or other CSF1R antagonists while not disrupting normal ATP binding to CSF1R.
• FIG. 4A demonstrates the dose-dependent induction of cell death in wild-type (WT) unedited human iPSC-microglia versus the G795A and G795C CSF1R mutant lines in response to PLX3397 and FIG. 4B shows the response to PLX5622.
• WT wild-type
• FIG. 4B shows the response to PLX5622.
• FIG. 4F provided representative images of cell density (phase-contrast microscopy, 1 st column) and fluorescent Caspase-3/7 activity (2 nd column) across each dose of PLX3397 and PLX5622.
• Strategy 2 PCR-mediated random mutagenesis will be used to introduce amino acid changes followed by exposure of iPS-microglia to CSF1R antagonists and then sequencing of surviving mutants to identify mutations that confer resistance to CSF1R antagonists, but which do not concurrently induce constitutively active or suppressed CSF1R signaling.
• a pool of iPSC or monocyte cell lines will be generated that carry random mutations in the CSF1R gene. This pool will then be differentiated into microglia and the survival of cells monitored in response to either CSF1/IL-34 withdrawal or CSF1R antagonist treatments. Cells that survive for longer under these conditions will be examined via PCR and sequencing to identity CSF1R mutations that may confer resistance to CSF1R antagonists.
• G795A and G795C iPSC-microglia exhibited no significant increase in caspase levels to increasing concentrations of either PLX3397, PLX5622, Edicotinib, or BLZ945, as compared to DMSO control treatment. These results indicate an acquired resistance to PLX treatment as a result of the genetically modified CSF1 receptor (see FIG. 4A, 4B, 4C, 4D, and 4E).
• iPS-microglia were plated at 70K cells per 96-well plate (6 wells per line per condition). At time 0, all microglia were treated with IncuCyte Caspase-3/7 Green Apoptosis Assay Reagent 1:1000.
• Embodiment 1 A modified human cell exhibiting differential resistance to a CSF1R antagonist.
• Embodiment 2 The cell of embodiment 1, comprising a nucleic acid encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• Embodiment 3 A modified human cell comprising a nucleic acid encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• Embodiment 4 The cell of any one of embodiments 1-3, comprising one or more genetic modifications in the CSF1R protein.
• Embodiment 5 The cell of embodiment 4, wherein the one or more genetic modifications results in a change in the amino add sequence of CSF1 R, the change optionally comprising the substitution of an amino add residue selected from G795, L785, M637, E633, and V647.
• Embodiment 6 The cell of any one of embodiments 1-5, wherein the one or more genetic modifications results in a modified ATP binding pocket.
• Embodiment 7 The cell of embodiment 6, wherein the modified ATP binding pocket has reduced binding space.
• Embodiment 8 The cell of embodiment 7, wherein the modified ATP binding pocket cannot bind a CSF1R antagonist.
• Embodiment 9 The cell of embodiment 6, wherein the modified ATP binding pocket can bind ATP.
• Embodiment 10 The cell of any one of embodiments 1-9, wherein the one or more genetic modifications in the CSF1 R protein do not interfere with ATP binding activity of the CSF1 R protein.
• Embodiment 11 The cell of any one of embodiments 1-10, wherein the one or more genetic modifications in the CSF1R protein do not induce constitutively active CSF1R signaling.
• Embodiment 12 The cell of embodiment 11, wherein the modified CSF1R protein is activated by a CSF1 ligand.
• Embodiment 13 The cell of embodiment 12, wherein the CSF1 ligand induces phosphorylation of the modified CSF1R protein.
• Embodiment 14 The cell of embodiment 11, wherein the modified CSF1R protein is activated by an IL-34 ligand.
• Embodiment 15 The cell of embodiment 14, wherein the IL-34 ligand induces phosphorylation of the modified CSF1R protein.
• Embodiment 16 The cell of embodiment 4, wherein the one or more genetic modifications are introduced ex vivo.
• Embodiment 17 The cell of embodiment 4, wherein the one or more genetic modifications are induced by transfecting or introducing into the cell a nucleic acid encoding a transgene, or by transduction or introduction of a targeted nuclease, nickase or base-editing effector or ribonucleoprotein complex.
• Embodiment 18 The cell of embodiment 17, wherein introducing the nucleic add encoding a transgene in a cell comprises contacting the cell with a viral vector.
• Embodiment 19 The cell of any one of embodiments 1-18, wherein the cell comprising a modified CSF1 R protein retains a gene expression profile of a cell comprising a wild-type CSF1R protein.
• Embodiment 20 The cell of any one of embodiments 1-19, further comprising one or more modifications in another gene.
• Embodiment 21 A modified human cell according to any one of embodiments 1-20 that is expressing CSF1R.
• Embodiment 22 The cell of embodiment 21, wherein the cell is induced and differentiated to express CSF1R and is selected from a group consisting of pluripotent stem cell, hematopoietic stem cell, an erythromyeloid progenitor, and hematopoietic progenitor cell.
• Embodiment 23 The cell of embodiment 22, wherein the cell is a CSF1R-expressing cell and is selected from a group consisting of microglia, macrophages, monocytes, or other phagocytes.
• Embodiment 24 A composition comprising a CSF1R-expressing cell according to any one of embodiments 20-23.
• Embodiment 25 The composition of embodiment 24, wherein the CSF1R-expressing cell is a CSF1R-expressing cell.
• Embodiment 26 The composition of embodiment 25, comprising a plurality of cells, wherein at least 0.1%, 1%, 5%, 10%. 20%, 30%, 40%, 50%. 60%, 70%, 80%, 90%, 95%, or 99% of the cells are CSF1R expressing cells having differential resistance to a CSF1R antagonist.
• Embodiment 27 A method of treating a subject, the method comprising: (a) administering a CSF1R antagonist to the subject in a quantity sufficient to inhibit a CSF1R signal in a cell of the subject; and (b) contacting the subject with a modified CSF1R-expressing cell having a differential resistance to the CSF1R antagonist
• Embodiment 28 A method of treating a subject, the method comprising: (a) contacting the subject with a modified CSF1R-expressing cell having a differential resistance to a CSF1R antagonist; and (b) administering the CSF1R antagonist to the subject in a quantity sufficient to inhibit a CSF1R signal in a cell of the subject.
• Embodiment 29 The method of embodiment 27 and embodiment 28, wherein the CSF1R-expressing cell is a CSF1R-expressing cell.
• Embodiment 30 The method of any one of embodiments 27-29, wherein the differential resistance to the CSF1 R antagonist is partial resistance or complete resistance to the CSF1 R antagonist.
• Embodiment 31 The method of any one of embodiments 27-30, wherein the modified CSF1R-expressing cell retains a gene expression profile of a wild-type CSF1R-expressing cell.
• Embodiment 32 The method of any one of embodiments 27-31, wherein the modified CSF1R-expressing cell expresses a gene product or other genetic modification useful to treat, cure, ameliorate, prevent or palliate a neurological disease.
• Embodiment 33 The method of embodiment 32, wherein the gene product is a transgene that is not otherwise expressed by the CSF1R-expressing cell.
• Embodiment 34 The method of embodiment 33, wherein the CSF1R signal that is inhibited by the CSF1R antagonist is proliferation or survival of a CSF1R-expressing cell that is endogenous to the subject.
• Embodiment 35 The method of any one of embodiments 27-34, wherein the CSF1R antagonist is administered to the subject in a quantity sufficient to reduce the proliferation and/or survival of the endogenous CSF1R-expressing cell relative to the modified CSF1R-expressing cell.
• Embodiment 36 A method of treating a subject, the method comprising: (a) contacting the subject with a modified CSF1R-expressing cell, and (b) differentially altering the proliferation or survival of an unmodified CSF1R-expressing cell relative to the modified CSF1R-expressing cell.
• Embodiment 37 The method of embodiment 36, wherein the modified CSF1R-expressing cell is a CSF1R-expressing phagocyte.
• Embodiment 38 The method of embodiment 36 and embodiment 37, wherein the modified CSF1R-expressing cell is partially resistant to a CSF1R antagonist.
• Embodiment 39 The method of embodiment 36, wherein the step of differentially altering the proliferation or survival of the unmodified CSF1R-expressing cell comprising administering the CSF1R antagonist to the subject in a quantity sufficient to reduce proliferation and/or survival of the unmodified CSF1R-expressing cell relative to the modified CSF1R-expressing cell.
• Embodiment 40 A nucleic acid composition encoding a modified CSF1R protein exhibiting differential resistance to a CSF1R antagonist.
• Embodiment 41 The composition of embodiment 40, wherein the differential resistance to the CSF1R antagonist is partial resistance or complete resistance to the CSF1R antagonist
• Embodiment 42 The composition of embodiment 40, wherein the differential resistance to the CSF1R antagonist is an increased resistance to the CSF1R antagonist.
• Embodiment 43 The composition of embodiment 40, wherein the differential resistance to the CSF1R antagonist is a decreased resistance to the CSF1R antagonist
• Embodiment 44 The composition of any one embodiments 40-43, wherein the modified CSF1R protein comprises one or more genetic modifications.
• Embodiment 45 The composition of embodiment 44, wherein the one or more genetic modifications results in a change in the amino acid sequence of CSF1 R, the change optionally comprising the substitution of an amino acid residue selected from G795, L785, M637, E633, and V647.
• Embodiment 46 The composition of embodiment 44, wherein the one or more genetic modifications results in a modified ATP binding pocket.
• Embodiment 47 The composition of embodiment 46, wherein the modified ATP binding pocket has reduced binding space.
• Embodiment 48 The composition of embodiment 47, wherein the modified ATP binding pocket cannot bind a CSF1R antagonist.
• Embodiment 49 The composition of embodiment 46, wherein the modified ATP binding pocket can bind ATP.
• Embodiment 50 The composition of embodiment 44, wherein the one or more genetic modifications in the CSF1 R protein do not interfere with ATP binding activity of the CSF1 R protein.
• Embodiment 51 The composition of embodiment 44, wherein the one or more genetic modifications in the CSF1R protein do not induce constitutively active CSF1R signaling.
• Embodiment 52 The composition of embodiment 51, wherein the modified CSF1R protein is activated by a CSF1 ligand.
• Embodiment 53 The composition of embodiment 52, wherein the CSF1 ligand induces phosphorylation of the modified CSF1R protein.
• Embodiment 54 The composition of embodiment 51, wherein the modified CSF1R protein is activated by an IL-34 ligand.
• Embodiment 55 The cell of embodiment 54, wherein the IL-34 ligand induces phosphorylation of the modified CSF1R protein.
• Embodiment 56 An expression vector comprising the nucleic acid composition of any one of embodiments 40-55 operably linked to an expression control sequence.
• Embodiment 57 A cultured cell transfected with the vector of embodiment 56, or a progeny of said cell, wherein the cultured cells express the polypeptide.
• Embodiment 58 An endogenous cell infected with the vector of embodiment 56, wherein the endogenous cells express the polypeptide.
• descriptions of the disclosure described herein using the phrase ‘comprising” includes embodiments that could be described as ‘consisting essentially of or “consisting of, and as such the written description requirement for claiming one or more embodiments of the present disclosure using the phrase “consisting essentially of or “consisting of is met.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biomedical Technology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Genetics & Genomics (AREA)
• Zoology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Wood Science & Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• General Engineering & Computer Science (AREA)
• Biophysics (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Developmental Biology & Embryology (AREA)
• Dermatology (AREA)
• Virology (AREA)
• Ophthalmology & Optometry (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Psychiatry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Priority Applications (10)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=83456857

Family Applications (1)

Country Status (8)

Cited By (2)

Citations (1)

Family Cites Families (35)

• 2022
  • 2022-04-01 CA CA3215311A patent/CA3215311A1/en active Pending
  • 2022-04-01 EP EP22782325.9A patent/EP4314003A4/en active Pending
  • 2022-04-01 DE DE112022000079.1T patent/DE112022000079T5/de not_active Withdrawn
  • 2022-04-01 AU AU2022252407A patent/AU2022252407A1/en active Pending
  • 2022-04-01 DE DE202022003066.5U patent/DE202022003066U1/de not_active Withdrawn - After Issue
  • 2022-04-01 WO PCT/US2022/023139 patent/WO2022212897A1/en not_active Ceased
  • 2022-04-01 JP JP2023559849A patent/JP2024513003A/ja active Pending
  • 2022-04-01 DE DE202022003132.7U patent/DE202022003132U1/de active Active
  • 2022-04-01 DE DE202022002866.0U patent/DE202022002866U1/de active Active
  • 2022-04-01 GB GB2219686.9A patent/GB2612467B/en active Active
  • 2022-12-21 US US18/069,543 patent/US12421517B2/en active Active
  • 2022-12-21 US US18/069,631 patent/US20230248775A1/en not_active Abandoned
• 2024
  • 2024-06-11 US US18/739,622 patent/US20250002920A1/en active Pending

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events